Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials

Recent phase 1–2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metastatic nasopharyngeal carcinoma (RM-NPC), however head-to-head comparison among these regime...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Jia-Wei, Li, Jun-Yan, Luo, Lin-Na, Wang, Zi-Xian, Chen, Yu-Pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593483/
https://www.ncbi.nlm.nih.gov/pubmed/31238988
http://dx.doi.org/10.1186/s40425-019-0636-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593483/
https://www.ncbi.nlm.nih.gov/pubmed/31238988
http://dx.doi.org/10.1186/s40425-019-0636-7

Ejemplares similares